Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies underwa ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

While announcing billions of dollars in new U.S. investments, company chief David Ricks called for an extension of 2017 tax ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

The live webcasts can be accessed on Neurocrine Biosciences' website under Investors at A replay of the webcasts will be available on the website approximately ...

JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated ...

Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Neurocrine Biosciences in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein now expects ...

Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...

Over the last 7 days, the United States market has dropped 2.2%, yet it remains up by 18% over the past year with earnings expected to grow by 14% per annum in the coming years. In this context, ...